The new immuno-oncology company is co-located in Cambridge and Rockville, Maryland, is backed by a $150 million Series A round led by Catalio Capital Management, Third Rock Ventures and Novo Holdings.
Source link
Surface Oncology CEO Rob Ross returns, with new $150M-backed startup
